Biotech / Medical
Trillium Therapeutics
An SI Board Since February 2014
Posts SubjectMarks Bans Symbol
166 50 0 TRIL
Emcee:  tuck Type:  Unmoderated
The following is how Trillium now thinks of itself as of 8/31/2017:

Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s lead program, TTI-621, is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (“do not eat”) signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (“eat”) signals. A Phase 1 clinical trial (NCT02663518) evaluating intravenous dosing of SIRPaFc in patients with advanced cancer is ongoing, and a second Phase 1 trial evaluating direct intratumoral injections is underway in solid tumors and mycosis fungoides (NCT02890368). TTI-622 is an IgG4 SIRPaFc protein, which is primarily being developed for combination therapy. An IND filing is targeted for 2H/17. Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties. Stemming from this platform, the company’s most advanced preclinical program is an orally-available epidermal growth factor receptor antagonist with increased uptake and retention in the brain. In addition, a number of compounds directed at undisclosed immuno-oncology targets are currently in the discovery phase.

The board logo is CD47 in complex with SIRP, the pathway targeted by the lead program.

Website: Trillium Therapeutics
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
166OT re garbled links: Old SI problem. The links have to be pasted because of thetuck-last Thursday
165 Wow. Don't know why the link gets garbled. Same thing goes for the searchscaram(o)uche-last Wednesday
164Authors all from Trillium ("triggers CD47-mediated tumor cell apoptosis&quoscaram(o)uche-last Wednesday
163 Overexpression of CD47 involved in abdominal aortic aneurysms scopeblog.stanforBulbaMan-February 17
162 I am not a subscriber to Sally's Blog, , though I&#ghmm-February 7
161 Janus Capital files, indicating that they've dropped below 5% ownership. Lscaram(o)uche-February 6
160 Same idea, different combo on mice. med.stanford.edusemi_infinite -February 4
159<Might be you really do need to get to close to 100% receptor occupancy to reMiljenko Zuanic1February 4
158So dramatic expansion in the size and scope of the intratumoral trials. I reallyBiomaven1February 3
157That's right, I should look at the bright side. He's the very best thatscaram(o)uche-January 23
156Who ever is pushing it help me sell my entire position. I am out. Best of luck Miljenko Zuanic-January 23
155"Got to watch for out of context with this cfo" Can you explain thisBladerunner17-January 23
154Someone pushed the bid to 8.90 this morning on arca and picked up a small numberscaram(o)uche-January 23
153THIS is why they have that tacky F-10 out there. If investors/traders can make scaram(o)uche-January 17
152The company also announced that Eric Sievers, MD, has transitioned from Chief Mescaram(o)uche1January 17
151"These additions to our management team further bolsters our planned pipeliscaram(o)uche-January 17
150Thank you! Be nice if they published it. Be nice if it was included in datascaram(o)uche-January 16
149I actually asked the company about SLAMF7 last May. They responded that they hadBiomaven-January 16
148Unfortunately, I can't see the figures with sufficient resolution to learn mscaram(o)uche-January 14
147(Published online: January 11, 2018) Accumulating data suggest that SIRPa–CD47 scaram(o)uche1January 14
146Mr. James Parsons Chief Financial Officer Mr. Parsons is responsible for financscaram(o)uche-January 12
145When your Business Development team is occupied with revising the header to a S.scaram(o)uche-January 12
144Maybe next decade (or next century, whatever) someone will turn eyes on them (TRMiljenko Zuanic-January 12
143I think (but I'm not 100% sure) that the 11/17/17 date in the PR about the MDewDiligence_on_SI-January 11 Forty Seven Inc. to Collaborate on a Novel Immuno-Oncology Coscaram(o)uche-January 11
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
Copyright © 1995-2018 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.